TheraNest vs Bristol Myers Squibb

Side-by-side comparison of AI visibility scores, market position, and capabilities

Bristol Myers Squibb leads in AI visibility (80 vs 52)
TheraNest logo

TheraNest

ChallengerMental Health Tech

Therapy Practice Management

Practice management and therapy notes software for mental health practitioners, acquired by Therapy Brands. Serves solo practices, group practices, and agencies.

AI VisibilityBeta
Overall Score
C52
Category Rank
#301 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
50
Perplexity
49
Gemini
54

About

TheraNest is a cloud-based practice management and clinical documentation platform for mental health practitioners, including therapists, social workers, counselors, and psychologists. Originally founded as an independent company, TheraNest was acquired by Therapy Brands, a technology roll-up focused on behavioral health software, which also owns Therapy Brands, ICANotes, and other mental health practice management systems. TheraNest serves a broad range of practice types from solo practitioners to large group practices and nonprofit agencies.\n\nThe platform provides scheduling, billing, telehealth, clinical notes, treatment planning, and client portal functionality in a unified interface. TheraNest is particularly recognized for its affordability and straightforward pricing model, which has made it a popular choice for practices with tight administrative budgets and those serving Medicaid populations. The product supports both individual and group therapy documentation workflows, including co-signature and supervision features relevant to practices employing pre-licensed associates.\n\nAs part of the Therapy Brands portfolio, TheraNest benefits from shared infrastructure investment and cross-selling opportunities, while maintaining its standalone brand and product identity. The mental health EHR market is competitive, with SimplePractice, TherapyNotes, and Jane App also vying for the small-to-mid-size practice segment. TheraNest's acquisition has allowed it to invest in product development while leveraging Therapy Brands' broader customer relationships and compliance infrastructure.

Full profile
Bristol Myers Squibb logo

Bristol Myers Squibb

LeaderHealthcare Tech

Enterprise

Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.

AI VisibilityBeta
Overall Score
A80
Category Rank
#18 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
78
Perplexity
78
Gemini
80

About

Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).

Full profile

AI Visibility Head-to-Head

52
Overall Score
80
#301
Category Rank
#18
80
AI Consensus
83
stable
Trend
stable
50
ChatGPT
78
49
Perplexity
78
54
Gemini
80
53
Claude
84
57
Grok
77

Key Details

Category
Therapy Practice Management
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only TheraNest
Therapy Practice Management

Integrations

Only Bristol Myers Squibb
Bristol Myers Squibb is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.